Epstein–Barr virus reprograms immune escape in nasopharyngeal carcinoma Authors: Qifang Liu, Yujing Tong, Tingting Sun, Linxi He, Xuewen Xu, Kai You Published: 2026 ABSTRACT ABSTRACTNasopharyngeal carcinoma (NPC) is an Epstein – Barr virus (EBV)-associated epithelial malignancy characterized by an immune-rich yet immunosuppressive microenvironment. EBV establishes an inflammatory but immune-tolerant ecosystem that underlies poor responses to immunotherapy. While prior studies have focused on single checkpoints such as PD-1/PD-L1, they often overlook the systemic immune reprogramming driven by EBV. Viral latent proteins, particularly LMP1, activate NF-κB and JAK – STAT signaling, inducing cytokine production, immune cell reeducation, and therapeutic resistance. This leads to upregulation of multiple checkpoint molecules, T-cell dysfunction, myeloid suppression, and immune exclusion. Consequently, anti-PD-1 therapies show limited efficacy, as tumors exploit alternative checkpoints (e.g. TIM-3, LAG-3, TIGIT) and stromal barriers. This review comprehensively summarizes EBV-driven immune remodeling in NPC and highlights emerging therapeutic strategies targeting both host immunity and EBV-associated signaling axes to overcome immune escape, enhance immunotherapy efficacy, and ultimately improve clinical outcomes.KEYWORDS: Nasopharyngeal carcinoma, Epstein–Barr virus, LMP1, immune escape, PD-L1, tumor immune microenvironment Introduction Nasopharyngeal cancer is a unique epithelial malignant tumor originating from the nasopharyngeal mucosa, with significant geographical and racial aggregation [1,2]. The disease is particularly prevalent among people in southern China, Southeast Asia, North Africa and some Arctic regions. Epidemiological studies consistently show that environmental exposure, genetic susceptibility and viral infection together affect the risk of disease. Dietary factors, such as eating salted foods, can increase the exposure of nitrosamines and other carcinogens [3,4]. The genetic variation of the host HLA gene site will affect immune recognition and antigen presentation. These factors together constitute a favorable environment for malignant transformation[5]. This epidemiological pattern distinguishes nasopharyngeal cancer from most other head and neck cancers[6]. The clinical manifestations of nasopharyngeal cancer are usually related to its anatomical location and early lymphatic metastasis tendency [7,8][9]. Patients often have enlarged lymph nodes in the neck, nasal congestion, nosebleeds or hearing loss. Many tumors are asymptomatic in the early stage[10]. Therefore, a considerable number of patients are already in the late stage when they are diagnosed. Because nasopharyngeal cancer is sensitive to radiation, radiotherapy is still the cornerstone of treatment [11,12]. Synchronous radiotherapy can improve the local control and survival rate of advanced patients. However, distant metastasis is still the main cause of treatment failure. These clinical challenges highlight the necessity of systemic treatment strategies. The biological characteristics of nasopharyngeal cancer are different from those of other head and neck squamous cell carcinomas [13,14]. Tumor cells usually show undifferentiated or poorly differentiated histological characteristics[15]. The peripheral stroma contains abundant immune cell infiltration. This feature once led to nasopharyngeal cancer, which was described as lymphoepithelioma. Immune cell infiltration includes CD8+ T cells, CD4+ T cells, B cells, macrophages and dendritic cells [16–18]. The presence of these cells initially suggests strong anti-tumor immunity[19][20],21. However, the clinical results do not reflect effective immune control. This paradox reflects the immunological complexity of nasopharyngeal cancer. The most significant biological feature of nasopharyngeal cancer is that it is almost universally associated with the Epstein-Barr (EB) virus[22]. EB virus infection proceeds the malignant transformation and persists in tumor cells during the progression of the disease [23,24]. The viral genome exists in the nucleus of cancer cells in the form of episome[25]. EB virus adopts type II latent procedure in nasopharyngeal cancer [2,16]. The program limits the expression of viral antigens while retaining its important carcinogenic function[26]. Key viral products include EBNA1, LMP1, LMP2A, non-coding EBERs and a variety of viral microRNAs. This limited expression pattern minimizes immune detection and maintains carcinogenic signal conduction. The latent EB virus protein can actively reshape the biological characteristics of host cells [27,28]. As a constituent active signaling molecule, LMP1 can simulate the activation of tumor necrosis factor receptors [29,30]. LMP1 binds to the connecting protein to drive the downstream NF-κB, MAPK and JAK-STAT signaling pathways. These pathways promote cell survival, proliferation and resistance. EBV also changes cell metabolism and epigenetic status. Viral microRNA will inhibit host cell apoptosis and immunoidentification-related genes. These effects together promote malignant transformation. Persistent EBV infection will produce continuous immune pressure in the tumor microenvironment. Viral antigens persist throughout the course of the disease. Host immune cells identify EBV antigens and initiate antiviral reactions [31,32]. However, tumor cells will gradually acquire the mechanism to inhibit immune attacks[33]. This process is similar to immune editing driven by chronic antigen exposure. EBV promotes this adaptation by regulating the expression of immune-related genes [34,35]. The virus will affect the production of cytokines and the mechanism of antigen presentation. Over time, this interaction will screen out tumor cell groups that can escape immune clearance[36]. Therefore, the existence of viruses shapes the evolution of tumors. Nasopharyngeal cancer shows a tumor microenvironment rich in immune cells, which is in stark contrast to its severe immunosuppression [37,38]. Histological examination shows that there is intensive lymphocyte infiltration in most tumors. Transcriptome analysis confirmed the high expression of immune-related genes. These characteristics classify nasopharyngeal cancer as an inflammatory tumor. Despite this inflammatory characteristic, effective anti-tumor immunity is rarely produced. Cytotoxic T cells often show dysfunction. Many immune cells show signs of depletion. This contradiction is the core problem of nasopharyngeal cancer biology. Multiple immunosuppressive mechanisms play a role at the same time in the microenvironment of nasopharyngeal cancer. Tumor cells highly express PD-L1, and PD-L1 inhibits T cell activation through the PD-1 signaling pathway. Chronic interferon-γ exposure maintains immune checkpoint expression and adaptive immune resistance. Medullary cells differentiate into inhibitory phenotypes. Tumor-related macrophages secrete inhibitory cytokines, such as IL-10 and TGF-β. Regulate the accumulation of T cells and further inhibit the immune response[39]. These mechanisms coexist. They work together to suppress antiviral and anti-tumor immunity[40]. EB virus plays a central role in regulating this immunosuppressive environment [41,42]. Viral proteins can directly induce immune checkpoint molecules[43]. The signaling pathway driven by EB virus promotes the secretion of chemokines, thus recruiting subgroups of inhibitory immune cells [44,45]. Viral microRNA interferes with the processing and presentation of antigens. EB virus also affects the spatial tissue in the tumor. Immune cells are usually excluded from direct contact with malignant epithelial cells. These effects show that the EB virus actively builds an immune escape mechanism. Viruses do not only coexist with immunosuppression. This review promotes the core concept that EB virus acts as an active builder of the immune escape mechanism in nasopharyngeal cancer. The virus latent program dynamically reprograms the tumor-immune interaction. These procedures shape immune infiltration, immune function and therapeutic response. Understanding this virus-host interaction provides a unified framework for explaining clinical results and a reasonable target for treatment. Future immunotherapy strategies must regard EB virus biology as the core determinant of nasopharyngeal cancer immune behavior. EBV latency programs in nasopharyngeal carcinoma EBV latency patterns and viral gene expression EB virus has established a highly specific latent procedure in nasopharyngeal cancer, which distinguishes it from other EB virus-related malignant tumors. Tumor cells always show the latent state of type II EB virus, which is characterized by limited viral gene expression but strong biological activity [46,47]. This latent pattern avoids the complete expression of immune dominant virus antigens. At the same time, the program retains the necessary carcinogenic and immune regulation functions, which consist of a bottom-up control system. This balance enables tumor cells infected with EB virus to survive under continuous immune surveillance. Therefore, the latency program reflects the evolutionary pressure exerted by the host’s immune system. Type II latency in nasopharyngeal cancer includes the expression of a specific group of viral products [48,49] (Figure 1). These products include EBNA1, LMP1, LMP2A, rich EBER non-coding RNA and complex EB virus-encoded microRNA. Each component plays a unique role in maintaining the persistence of the virus and promoting tumor adaptability. EBNA1 supports the replication and isolation of the viral genome during cell division [50,51]. LMP1 and LMP2A simulate host signal receptors and transmit survival signals. EBERs and viral microRNA regulate host transcription and immune response. This expression spectrum remains stable in primary tumors and metastatic foci. This consistency highlights the selective advantage of the latent state. EBV infection and protein expression during latent and replicative phases. EBV latency can be categorized into three types: latency I, latency ii, and latency iii. Each latency phase produces a limited and unique set of viral proteins and RNAs. The antigen map with limited latent state of type II profoundly affects immune-identification. Due to its glycine-alanine repeat domain, EBNA1 can escape the effective presentation of MHC I molecules. Compared with type III latent state, the expression level of LMP1 and LMP2A is lower [52,53]. Viral microRNA further inhibits the mechanism of antigen processing and presentation. These mechanisms reduce the visibility of the virus to cytotoxic T lymphocytes. The immune system can still sense the presence of the virus, but the immune clearance is inefficient. This controlled hidden state supports the long-term survival of the tumor. There is space-time heterogeneity in virus expression programs. Some tumor regions show high LMP1 expression, while other areas give priority to the expression of viral microRNA [54,55]. Environmental factors such as hypoxia and inflammatory cytokines affect the level of viral gene expression. These fluctuations enable tumor cells to dynamically adapt to immune pressure. Therefore, the latent program is a flexible regulation system. This adaptability enhances the immune escape ability of tumor cells, and also increases the difficulty of treating EB virus antigens. Cell-intrinsic effects of EBV latent genes The EBV latent gene has a significant impact on the internal mechanism of cells and promotes the survival and malignant progression of nasopharyngeal cancer. The core signaling pathway of viral proteins is reprogrammed to control proliferation, apoptosis and cell stress response. As a component active signal stent, LMP1 simulates the binding of tumor necrosis factor receptors. This activity drives the continuous activation of NF-κB, MAPK and JAK-STAT pathways. This continuous signaling flow not only promotes the survival of tumor cells but also directly induces the transcription of PD-L1 [56]. This means that the expression of PD-L1 is not merely the result of an adaptive immune response. LMP2A further enhances cell survival by simulating continuous B cell receptor signal transmission. In epithelial cells, LMP2A activates the PI3K-AKT signaling pathway [57,58]. This pathway promotes metabolic adaptation and anti-apoptosis. LMP2A also inhibits the differentiation process that would limit tumor growth [59,60]. EBNA1 plays an indirect role by inducing genome instability and oxidative stress tolerance. These viral products work together to maintain the long-term survival of tumor cells. The viral gene continues to function, and its influence accumulates over time. Chronic inflammatory signal conduction is another key result of latent infection of EBV. LMP1 induces the continuous production of cytokines and chemokines (including IL-6, IL-8, CCL2 and CXCL10) [56,61]. These mediators work in the form of autosecretion and parasecretion. Autosecretory signal conduction enhances the survival and proliferation of tumor cells. Pasosecretory signal conduction reshapes the tumor microenvironment. Immune cells and matrix cells respond to these signals. The inflammatory state forms a self-sustaining state. This chronic inflammation is different from the acute antiviral reaction. Signal conduction persists and cannot subside effectively. EBV-encoded microRNA amplifies these effects by finely regulating host gene expression. The negative regulatory factor of viral microRNA inhibits inflammatory signals. They also target genes involved in cell apoptosis and immune activation. This regulation enhances the robustness of signal transmission and minimizes immune detection. As a result, the surface of tumor cells is inflammatory, but it can resist immune-mediated destruction. These intrinsic changes show how EBV integrates carcinogenic signals with immunomodulation. Therefore, virus latency not only promotes tumor growth, but also allows the tumor to escape immune attack. EBV as a continuous immune stimulus The development of nasopharyngeal cancer is carried out under the condition of continuous immune stimulation driven by persistent EBV infection. The viral genome exists in every tumor cell. The viral products are continuously expressed throughout the course of the disease. The immune system recognizes EBV-derived antigens and nucleic acids. This identification will trigger a continuous antiviral immune response, and this pressure never disappeared. Therefore, the evolution of tumors occurs in a continuous immune surveillance environment. Chronic antigen exposure will reshape the function of immune cells in the tumor microenvironment. CD8+ T cells initially produce cytotoxic activity against EBV antigen [62,63]. Over time, repeated stimulation can lead to functional failure. Depleted T cells can regulate inhibitory receptors such as PD-1, TIM-3 and LAG-3. The production of effect cytokines is reduced, and the proliferation ability is reduced. These changes have reduced the antiviral effect. The immune response still exists, but it has been invalidated. Continuous immune stress also drives the selection of immune escape tumor cell phenotype. Tumor cells with up-regulated PD-L1 have a survival advantage. Reduce the antigen-presented cells to escape immune killing. Viral microRNA and host epigenetic changes support this choice [64,65]. After continuous cell generations, immune resistance cloning dominates. This process is similar to Darwin’s choice. The immune system inadvertently shaped the tumor. The EB virus is the driving force of this process. The interaction between EB virus and host immunity produces a stable but pathological balance [66,67]. The immune system controls the spread of the virus, but it cannot remove tumor cells. Tumor cells tolerate immune attacks and use inflammatory signals to promote their own growth. This balance maintains the persistence of the disease. Therapeutic intervention will break this balance. Immune checkpoint blocking can activate depleted T cells. However, the adaptive drug resistance driven by EB virus usually limits the durability of the effect. Understanding EB virus as a continuous immune stimulus can help explain the treatment response and failure of nasopharyngeal cancer. LMP1 as a central immune-modulating oncoprotein Structural features and signaling properties of LMP1 LMP1 is the most effective carcinogenic and immunomodulatory protein encoded by EB virus in nasopharyngeal cancer. LMP1 is a transmembrane protein located in the plasmic membrane and the inner cell membrane [29,68]. The protein contains six transmembrane domains and a long cytoplasmic C-terminal tail. The tail mediates downstream signal conduction. Unlike host receptors, LMP1 can be activated without lind binding. The protein continues to send signals. This characteristic gives LMP1 a lasting biological activity. The C-terminal domain of LMP1 contains conservative activation regions, which can recruit host linking proteins [69,70] (Figure 2). These regions interact with TRAF and TRADD, which are key mediators for inflammatory signal conduction. Through these interactions, LMP1 simulates continuously activated tumor necrosis factor receptors. This simulation bypasses the normal regulation checkpoint. Even in the absence of extracellular stimulation, signal conduction remains active. Therefore, tumor cells can continuously receive survival signals and inflammatory signals. This autonomy distinguishes virus signal transmission from the signal pathway controlled by the host. Schematic overview of LMP1 structure and signaling. LMP1 contains six transmembrane loops and a cytoplasmic tail with two c-terminal activating regions (CTAR1 and CTAR2). These regions recruit adaptor proteins and activate downstream pathways including NF-κB, PI3K–AKT, ERK–MAPK, JNK, JAK-STAT, and p38/MAPK that contribute to oncogenic and immunomodulatory functions. Membrane aggregation enhances the signal strength of LMP1. LMP1 molecules gather in lipid rafts and intracellular vesicles. This aggregation promotes the effective recruitment and signal amplification of junction proteins. Cellular stress and hypoxia further enhance the aggregation of LMP1 [71,72]. These conditions are very common in solid tumors. Therefore, the activity of LMP1 will adapt to the tumor microenvironment. The protein indirectly perceives the cell environment, and the signal strength also changes accordingly. The simplicity of the structure supports the diversity of its functions. LMP1 lacks enzyme activity, but acts as a signal transduction platform [73,74]. This design enables it to interact with multiple host signaling pathways at the same time. In addition, the structure also reduces immunogenicity. The expression level of LMP1 is relatively low, but the signal output is still high. This high efficiency helps tumor cells escape immune surveillance, and also highlights the core role of LMP1 in nasopharyngeal cancer biology. LMP1-driven inflammatory and oncogenic signaling pathways LMP1 activates multiple core signaling pathways that control inflammation, immunity and cell fate. The NF-κB signaling pathway is the main downstream pathway. LMP1 induces classical and non-classical NF-κB activation. This activation increases the transcription of anti-apoptotic genes, inflammatory mediators and immunomodulatory factors. The NF-κB signaling pathway is continuously activated and cannot be completely subsided [75,76]. Therefore, tumor cells are in a state of continuous inflammatory activation. LMP1 also activates the JAK-STAT pathway, especially STAT3. STAT3 activation promotes cell proliferation, survival and immunosuppression. LMP1-induced cytokines, such as IL-6, enhance the STAT3 signaling pathway through autosecreting loops [77,78]. This enhancement stabilizes the activation of the pathway. The STAT3 signaling pathway inhibits antigen presentation and promotes immune tolerance [79,80]. Tumor cells acquire resistance to cytotoxic immune response. The pathway also affects the surrounding immune cells. Macrophages and T cells react to STAT3-driven cytokines. The MAPK pathway is involved in additional regulatory levels. LMP1 activates ERK, JNK and p38 signal pathways. These pathways regulate the cell cycle process and stress response. The MAPK signaling pathway supports epithelial-interstitial transformation and invasion behavior [81,82]. The expression of inflammatory genes also increases. These effects integrate carcinogenic growth with immunomodulation. Tumor cells adapt to the unfavorable microenvironment and reshape the collection of immune cells. The crosstalk between these pathways amplifies the biological output. NF-κB, STAT3 and MAPK signaling pathways are mutually enhanced. The inhibitory feedback mechanism weakens with the passage of time. Viral microRNA further inhibits negative regulatory factors. The network produces strong signal stability. The system can resist disturbances. This resistance makes therapeutic inhibition complicated. Therefore, LMP1 plays the role of the main regulatory factor, not the role of a single pathway activation factor. LMP1-mediated immune regulation and checkpoint regulation LMP1 has a direct effect on immune regulation in nasopharyngeal cancer. A key result is to induce the expression of PD-L1 in tumor cells. LMP1 activates PD-L1 transcription through NF-κB and STAT3 signaling pathways. Interferon reaction elements are also involved in it. The resulting expression of PD-L1 inhibits the activity of CD8+ T cells by binding to PD-1 [83,84]. This inhibitory effect reduces cytotoxicity and promotes T cell depletion. The immune checkpoint pathway occupies a dominant position. LMP1 also regulates other immunosuppressive molecules. In LMP1-positive cells, the expression of galactose-9, B7 family members and TIM-3 ligands increased. These molecular synergies enhance the inhibition of the immune microenvironment. A variety of inhibitory signals converge in effect T cells. This redundancy mechanism ensures immune escape. Blocking a single pathway may not fully restore immunity. The production of cytokines and chemokines further enhances immune regulation. LMP1 induces the secretion of CCL2, CCL5 and CXCL10 [85,86]. These factors will recruit immune cells into the tumor. However, the collected cells usually differentiate into inhibitory phenotypes. Tumor-related macrophages acquire immunomodulatory function. Regulatory T cell aggregation. The effect immune response is weakened. The surface of the tumor seems to be rich in immune cells, but it is functionally silent. Space organization strengthens these effects. The expression of LMP1 is usually concentrated on the edge of the tumor and the front of the invasion. These regions show a high level of immune checkpoint expression and immunosuppression. Immune cells are trapped in the matrix compartment. Direct contact with tumor cells is reduced. Therefore, LMP1 not only affects immune signal conduction, but also immune structure. This spatial control enhances the immune escape ability of the tumor. This also explains the heterogeneity of the immunotherapy response. In a word, LMP1 plays the role of core immune regulation of cancer proteins in nasopharyngeal cancer. This protein integrates carcinogenic signal conduction and immunosuppression. The LMP1-driven pathway establishes a state of chronic inflammation but immune tolerance. This state supports the persistence of the tumor. The treatment strategy must take into account the biological characteristics of LMP1. It may be the most feasible way to target the downstream immune response. EBV-Driven immune checkpoint regulation Mechanisms of PD-L1 induction in nasopharyngeal carcinoma Immune checkpoint regulation is one of the most prominent immunological characteristics of EB virus-related nasopharyngeal cancer. Malignant epithelial cells in tumor tissue often express PD-L1 [87,88]. Immune cells in the tumor microenvironment also express PD-L1. Clinical studies have repeatedly confirmed that this pattern is associated with positive EB virus. Therefore, the virus occupies a central position in the regulation of immune checkpoints. The expression of PD-L1 does not occur randomly, and the EB virus latency program will positively affect this result. LMP1 is the main viral driving factor induced by PD-L1 in nasopharyngeal cancer. The protein activates the NF-κB signaling pathway in a component way. The activated NF-κB directly binds to the regulatory region of the PD-L1 gene, resulting in transcription enhancement, and this effect persists [89,90]. LMP1 can also activate the JAK-STAT pathway, especially STAT3, thus further stabilizing the transcription of PD-L1. Autosecreting cytokines strengthens this process. The secretion of IL-6 maintains the phosphorylation of STAT3. Tumor cells have achieved autonoimmune checkpoint expression independent of the immune environment. The interferon signaling pathway provides additional regulatory mechanisms. The activated immune cells respond to the EBV antigen and release interferon-γ, which binds to STAT1 and IRF1 in tumor cells [91]. These transcription factors upregulated the expression of PD-L1. This process represents the classic adaptive immune resistance. On the contrary, immune activation enhances immunosuppression. EBV ensures continuous exposure of interferon through continuous antigen presentation. Therefore, the expression of PD-L1 is continuously increased, not briefly. Post-transcription regulation further enhances the stability of PD-L1. EBV-encoded viral microRNA inhibits the negative regulatory factors expressed at immune checkpoints. These microRNAs target host genes involved in mRNA degradation and immune activation. The PD-L1 protein level remains high. At the same time, the antigen processing route is weakened. Immune recognition ability declines. The combined effect of these mechanisms enables EBV-positive tumor cells to maintain lasting immune protection. Beyond PD-L1: expansion and integration of inhibitory immune network The immunosuppression of EBV-driven in nasopharyngeal cancer is far more than the PD-1-PD-L1 axis. Tumor cells usually express multiple immunosuppressive ligands at the same time. The expression of EBV latent genes supports this synergistic extension. Galactose aglutinin-9, TIM-3 ligand and other members of the B7 family all showed high expression in EBV-positive tumors [92]. Each ligand binds to different inhibitory receptors on immune cells. This combination is more effective in inhibiting effect immunity than a single pathway. The inflammatory signaling pathway driven by LMP1 provides the transcription basis for the inhibitory network. NF-κB and STAT3 regulate a wide range of immunomodulatory genes. These transcription factors do not work in isolation. The interaction between channels enhances the suppression output. Tumor cells have gained redundancy in immunosuppression. Blocking an immune checkpoint pathway does not affect the function of other pathways. This redundancy explains the reason for the poor clinical efficacy of single-drug treatment. The response of immune cells to this inhibitory environment is dynamic. CD8+ T cells exposed to a variety of immune checkpoint lids will cause severe immune failure. Cytotoxic activity decreases, cytokine production decreases, and metabolic adaptability decreases. CD4+ T cells turn to the state of regulatory T cells and dysfunctional auxiliary T cells [14,93]. Regulatory T cells ampliate and inhibit neighboring immune cells. Although the immune system still exists, its function is limited. Immune checkpoint regulation also extends to nonmalignant cells in the tumor microenvironment. Tumor-related macrophages highly express PD-L1 and other inhibitory ligands. These macrophages receive signals from tumor cells infected with EBV through cytokines and growth factors. Macrophages acquire inhibitory phenotypes and directly inhibit the activation of T cells. The immunosuppressive effect spreads to a variety of cell types. Therefore, EBV-driven immune regulation plays a role at the ecosystem level rather than at the single cell level (Figure 3). EBV-driven immune checkpoint regulation. LMP1 signaling (via TRAF2) activates NF-κB, JAK–STAT and MAPK pathways to sustain PD-L1 induction in nasopharyngeal carcinoma, while EBV-encoded microRNAs suppress negative regulators to stabilize immune checkpoint expression in the tumor microenvironment. EBV-associated cytokines and growth factors promote dynamic inhibition of immune cells, leading to reduced CD8+ T-cell cytotoxicity/cytokine output/metabolic adaptability, CD4+ T-cell skewing toward regulatory or dysfunctional helper states, and TAM-mediated suppression of T-cell activation. Spatial and temporal dynamics of immune checkpoint expression The immune checkpoint regulation of nasopharyngeal cancer shows significant spatial heterogeneity. There are differences in the expression of PD-L1 in different regions of tumors. High expression is usually located at the tumor-interstitial junction. The immune cells in these areas are strongly infiltrated. Chronic interferon signals are concentrated at these boundaries. EBV-positive tumor cells respond by local increase in checkpoint expression. Spatial adaptability enhances immune escape. Time dynamics further affect the regulation of checkpoints [13,94]. Early lesions usually show moderate immune activation and limited checkpoint expression. As the tumor progresses, the immune pressure increases. The EBV-driven signal path promotes the gradual upward adjustment of checkpoints. Treatment and intervention will change these dynamics. Radiotherapy and chemotherapy can induce inflammation and antigen release. The expression of the checkpoint increased accordingly. The incubation period of EBV will amplify this adaptability. Over time, immunosuppression becomes more entrenched. Spatial immune rejection is a functional consequence of checkpoint regulation [95,96]. Immune cells often gather in the interstitial compartment. The checkpoint ligands gather at the physical barrier. These barriers will reduce the binding of cytotoxic drugs. EBV regulates the gradient of chemokines and adhesion molecules [97], causing immune cells, mainly inhibitory myeloid cells and exhausted T cells, to be trapped in the tumor stroma, showing a restricted migration. It may mean that EBV not only controls molecules and cells, but also spatial layout. This spatial rejection is the fundamental reason why immunotherapy drugs are difficult to penetrate. Abnormal angiogenesis and the expression of adhesion molecules also limit the extravasation and infiltration of CAR-T cells, which inhibited the application of CAR-T therapy. Immune escape shows structural characteristics. These spatial and temporal characteristics deeply affect the clinical response of immunotherapy. Tumors with uniform expression of immune infiltration and checkpoints may respond well to PD-1 blocking therapy. The effect of tumors with immunorejection zone ventricularization is usually limited. There will be a compensatory inhibitory pathway during the treatment process. The generation of drug resistance. Understanding checkpoint regulation as a dynamic process driven by EBV helps to explain the difference in treatment results. Therefore, EBV-driven immune checkpoint regulation is the core mechanism of nasopharyngeal cancer immune escape. The virus latent program maintains chronic inflammation while strengthening immunosuppression. Multiple inhibitory pathways work at the same time. Space tissue strengthens molecular inhibition. Targeting immune checkpoints without solving the EBV-driven regulation may only bring short-term effects. Lasting control requires integrated strategies to destroy the immune engineering of the virus. EBV and remodeling of the tumor immune microenvironment EBV-driven regulation of T-cell infiltration, differentiation, and exhaustion Nasopharyngeal cancer is one of the most immune-reactive microenvironments in epithelial cancer, and EB virus plays a decisive role in shaping this microenvironment. A large number of CD8+ T cells and CD4+ T cells persist in tumor tissue, reflecting strong immune recruitment [98]. The viral antigen expressed by tumor cells infected with EB virus continuously stimulates immune recognition. The chemokine induced by EB virus latent protein promotes the migration of lymphocytes to the tumor region. The immune system shows a strong response at the recruitment level. Therefore, the tumor shows immune activity. Functional analysis reveals that there is a significant disconnect between immune existence and immune efficacy. Most infiltrated T cells in nasopharyngeal cancer show the characteristics of functional exhaustion [99,100]. Long-term exposure to antigens derived from EB virus will continuously activate T cell receptors. This continuous stimulation drives gradual transcriptional remodeling. Transcription factors related to exhaustion dominate. The effect process is weakened. T cells lose their proliferation ability and cytotoxic function. These cells are still alive, but they cannot remove tumor cells. Signal conduction driven by EBV in tumor cells will actively aggravate the depletion of T cells. LMP1-mediated NF-κB and JAK-STAT activation induced high expression of PD-L1 and other inhibitory ligands, which actively reprogram the tumor microenvironment and systematically suppress the anti-tumor immune response. Signal integration tends to be immune tolerance rather than activation. Tumor cells also secrete immunosuppressive cytokines, such as IL-10 and TGF-β [101,102], inhibiting the differentiation of T cells and promoting the phenotype of regulatory T cells (Tregs). They consist of the immunosuppressive mechanism of the primary lesion. Therefore, EBV shapes the fate of T cells through contact dependence and solubility mechanisms. The CD4+ T cell group undergoes parallel reprogramming. Chronic viral inflammation inhibits the differentiation of effective auxiliary T cells. Under continuous inhibitory signal conduction, the polarization of Th1 is weakened. Tregs accumulate in the tumor microenvironment. These cells inhibit neighboring effect T cells through cytokine secretion and intercellular contact. The immune balance gradually changes to the direction of tolerance. Antiviral immunity is inhibited. Spatial tissue further aggravates T cell dysfunction. In many tumors, T cells gather in the matrix compartment instead of infiltrating the tumor nest. Tumor cells infected with EBV regulate the chemokine gradient and promote their peripheral positioning. The expression of adhesion molecules further limits the migration of T cells [29,103]. Physical isolation reduces the direct cytotoxic effect. Immune rejection has become a structural mechanism. Therefore, the influence of the virus is not limited to molecular signal conduction, but also extends to the spatial immune structure. Time dynamics strengthens these patterns. Early lesions may show partial effect activity. The progression of the disease will enhance the mechanism of T cell depletion. The inflammation caused by treatment will temporarily enhance immune activation. The adaptive resistance driven by EBV will quickly offset this effect. T cells reenter a state of exhaustion. Persistent immunity is still difficult to achieve. Therefore, EBV establishes a stable but pathological balance between immune activation and immunosuppression (Figure 4). The NPC immune microenvironment. Schematic illustrating the induction of NF-κB and STAT3 signaling pathways and multiple immune cytokines by LMP1 in cancer cells resulting in cancer cell growth, angiogenesis. EBV-mediated reprogramming of myeloid cells and innate immune suppression In nasopharyngeal cancer, medullary cells are the main and highly plastic components in the tumor immune microenvironment. Tumor-related macrophages are concentrated in large numbers in EBV-positive tumors. Medullary inhibitory cells (MDSC) are also significantly amplified [104,105]. EBV-infected tumor cells actively drive this aggregation. The viral latent program induces the secretion of chemokine and growth factor, thus recruiting circulating mononuclear cells. Subsequently, monocytes rapidly differentiated into inhibitory phenotypes. Macrophages exposed to EBV-driven inflammatory environments will undergo profound functional reprogramming. These cells upregulate PD-L1, IL-10 and enzymes involved in amino acid metabolism (such as argininase-1). The ability to present antigens decreased. The expression of co-stimulants is weakened. Macrophages lose the activity of killing tumor cells. These cells turn to support immune tolerance. The inherent immune system is transformed into an immunomodulatory system. EBV-induced cytokines, such as IL-6 and CSF1, can stabilize the phenotype of inhibitory macrophage [106,107]. Autosecretion and parasecretory loops further strengthen this state. Macrophages secrete additional inhibitory mediators to inhibit the activation of T cells. These signals also promote the amplification of regulatory T cells. Congenital and adaptive immunosuppression are interrelated, and the immune escape mechanism is enhanced. Inhibitory cells derived from the medullary system further aggravate immune dysfunction. Chronic EBV-driven inflammation supports the amplification and survival of these cells. These cells inhibit the reaction of T cells through a variety of mechanisms. Reactive oxygen will destroy the signal conduction of T cell receptors. Nitric oxide will interfere with the production of cytokines. Nutritional depletion will limit the proliferation of T cells. Inhibition occurs at the level of metabolism and signal conduction. Under this pressure, adaptive immunity collapses. The function of dendritic cells is also impaired. The inflammatory environment associated with EBV can damage the maturation of dendritic cells. The expression of co-stimulating molecules is reduced. The ability to process and present antigens is weakened. The effective activation of initial T cells has become rare. Immunity renewal failed. Even if depleted T cells are activated by treatment, insufficient antigen presentation will limit the continuous immune response. Therefore, the EB virus fundamentally destroys the immune function. The spatial tissue of myeloid cells strengthens immunosuppression. Macrophages and inhibitory cells are usually located on the edge of the tumor. These cells form a functional barrier between tumor cells and effector lymphocytes. T cells will encounter inhibitory signals before reaching malignant epithelial cells. Immune attacks become indirect. Physical positioning and molecular inhibition complement each other. EBV-driven crosstalk networks and spatial immune ecosystem remodeling The tumor immune microenvironment of nasopharyngeal cancer stems from the continuous and coordinated interaction between EB virus-infected tumor cells and peripheral immune cells and matrix cells. Tumor cells act as active signal hubs. The viral latency program regulates the secretion of cytokines, chemokines and growth factors. These mediators affect the recruitment, differentiation and survival of immune cells, which constitute mechanisms of lymph node metastasis. This kind of communication is continuous, enabling the system to maintain itself. The parasecretory feedback loop stabilizes immunosuppression [108,109]. Tumor-derived IL-6, TGF-β and VEGF promote the formation of inhibitory immune phenotypes. Immune cells react by producing additional inhibitory mediators to further inhibit the effect function. EB virus maintains the system by maintaining inflammatory signals in tumor cells. The persistent presence of the virus ensures the continuity of the system and consolidates the immune escape mechanism. Extracellular vesicles provide another mechanism for immune remodeling. EBV-positive tumor cells release vesicles containing viral proteins, viral RNA and host immunomodulatory molecules. These vesicles interact locally and far-distance with immune cells. Macrophages and dendritic cells can efficiently swallow these vesicles, followed by functional reprogramming. The inhibitory phenotype spreads spatially, and the influence of the virus goes beyond direct cell contact. Fibroblasts and extracellular matrix components are integrated into this network. EBV-driven inflammation activates matrix cells. Cancer-related fibroblasts produce extracellular matrix proteins that limit the migration of immune cells and form physical barriers. It is difficult for T cells to penetrate the tumor nest, and immune rejection is strengthened. Structural remodeling is consistent with molecular inhibition. The spatial structure consolidates immune dysfunction. Effect T cells are limited to the matrix region. Inhibitory medullary cells occupy the tumor boundary. Tumor cells occupy a protected microenvironment. This organizational structure limits effective immune surveillance. The EBV-driven signal pathway is the basis of this structure. The virus latent program coordinates molecular and spatial immune remodeling. The evolution of time has strengthened this ecosystem [110,111]. Early immune response shapes selection pressure. Tumor cells and immune cells evolved together under the influence of EBV. Inhibitive network expansion. The structural barrier is mature. Therapeutic intervention will temporarily disrupt the system. The adaptability of EBV-driven restores immune escape. The ecosystem maintains resilience. In a word, EBV-driven tumor immune microenvironment remodeling defines nasopharyngeal cancer as an immunoadaptive malignant tumor shaped by the persistence of the virus. The virus latent program integrates the internal signaling pathway of the tumor with immune cell reprogramming and spatial tissue. The immune microenvironment becomes inflammatory, but it is functionally silent. This remodeling explains the reason for the limited durability of immune checkpoint blocking therapy. Successful treatment requires the destruction of these integrated networks. Clinical implications and immunotherapy strategies Immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma Immune checkpoint blocking therapy reshapes the treatment pattern of nasopharyngeal cancer, especially in recurrent and metastatic diseases. Clinical trials show that PD-1 inhibitors can induce persistent remission in some patients. EBV-positive tumors usually show high PD-L1 expression and intensive immune infiltration. These characteristics support its sensitivity to immune checkpoint blocking therapy. However, the remission rate is still not high, and the long-term therapeutic effect varies greatly. The biological characteristics of EBV help explain this difference. Virus latency will maintain chronic inflammation and immune exhaustion. PD-1 blocking therapy can reactivate the depleted CD8+ T cells in some patients [112]. These cells recovered their cytotoxicity and proliferation ability, and then the tumor subsided. However, in other patients, the compensatory inhibition pathway limited the therapeutic effect. Tumor cells and immune cells adapt quickly and eventually develop drug resistance (Figure 5). Clinical implications and immunotherapy strategies in EBV-positive nasopharyngeal carcinoma. PD-1 blockade yields durable responses in a subset but remains heterogeneous due to EBV-driven chronic inflammation, T-cell exhaustion and compensatory inhibition, with treatment timing influencing adaptive resistance. EBV DNA kinetics plus PD-L1, immune gene signatures and spatial immune profiling support improved patient stratification and rational combination therapy. Clinical observations show that there are differences in the treatment response patterns of EBV-positive nasopharyngeal cancer and EBV-negative head and neck tumors. The antigenicity of the virus enhances the basic immune identification. At the same time, EBV-driven immunosuppression limits its complete reactivation. The immune system is in a state of momentum but suppression. Immune checkpoint inhibitors can release partial inhibition. But complete immune recovery rarely happens. Treatment-related inflammation will also interact with the EBV signaling pathway. Radiotherapy and chemotherapy will increase antigen release and cytokine production. These effects may enhance the response of immunotherapy. However, inflammatory signals can also induce adaptive immune resistance by upregulating immune checkpoints. The timing and order of treatment will affect the result of treatment. Understanding the immune dynamics driven by EBV is crucial for clinical decision-making. EBV-related biomarkers and patient stratification Effective immunotherapy requires accurate patient stratification. EBV-related biomarkers provide a unique opportunity for nasopharyngeal cancer. Circulating EBV DNA can be used as a sensitive indicator of tumor load and treatment response. The decline in EBV DNA levels is associated with clinical benefits. An increase in the level indicates recurrence. The biomarker reflects the size of the tumor and the activity of the virus. The expression of tumor PD-L1 is still a common predictor of immunotherapy response. In nasopharyngeal cancer, PD-L1 expression is usually associated with EBV positive and inflammatory signaling pathways [113,114]. However, the predictive value expressed by PD-L1 alone is limited. Some tumors with high expression of PD-L1 did not respond to treatment, while some tumors with low expression of PD-L1 were unexpectedly effective. The immune gene expression spectrum provides additional stratification tools. The transcription spectrum reflecting the interferon signaling pathway, T cell depletion and medullary inhibition is related to the treatment results. EBV-positive tumors usually exhibit mixed immune phenotypes, which include both the characteristics of immune activation and immunosuppression. Compound biomarkers may better reflect this balance. Spatial immune spectrum analysis further optimizes patient selection. Immune infiltration is limited to tumors in the stitial region [115,116]. The response to immune checkpoint blocking therapy is limited. Tumors in direct contact with the immune system respond better to treatment. EB virus affects the spatial tissue of the immune system. Combining viral markers with spatial immune characteristics may improve the accuracy of prediction. Precision immunotherapy relies on this comprehensive method. Combination strategies informed by EBV-driven immune biology Monotherapy immunocheckpoint blocking therapy is not very effective for many patients with nasopharyngeal cancer[117]. The combined treatment strategy aims to overcome immune drug resistance driven by EB virus. The reasonable combined treatment plan is aimed at the complementary mechanism[118]. These methods seek to restore immune function while limiting adaptive immune escape. The combined application of PD-1 blocking and chemotherapy can enhance antigen release and immune activation [119,120]. Chemotherapy can reduce the immunosuppressive cell group. Radiotherapy can induce immunogenic cell death. These treatments can enhance the signal conduction of interferon. EBV-positive tumors respond differently to these changes. The correct order of treatment is still crucial. Excessive inflammation may enhance the expression of checkpoints. Targeting EBV-driven signal pathways provide more opportunities. Inhibiting the JAK-STAT or NF-κB signaling pathway may reduce immunosuppression[121]. These pathways support checkpoint expression and medullary reprogramming[122]. Regulating inflammatory signal conduction may make tumors more sensitive to immunotherapy[123]. Clinical transformation needs to be carefully weighed. Host immunity must remain intact. Emerging strategies include EBV-specific immunotherapy. Transient T cell therapy for EB virus antigen shows a good prospect. Therapeutic vaccines aim to enhance antiviral immunity. These methods directly utilize the antigenicity of the virus. The combined application of EB virus targeted therapy and immune checkpoint blocking therapy may produce synergistic effects [124,125]. Viral antigens have tumor specificity, which makes immune activation more accurate. Clinical success depends on the integration of viral biology into the design of treatment plans. EB virus is both an immunostimulating factor and an immunosuppressant. Treatment must deal with these two effects at the same time. Personalized combined treatment guided by EB virus and immune biomarkers represents the future development direction. Nasopharyngeal cancer is a typical model of virus-related cancer immunotherapy. Continuous progress depends on the combination of clinical strategies with EB virus-driven immune mechanisms. Mechanisms of primary and acquired resistance Intrinsic immune resistance and baseline non-responsiveness Despite EBV positive and immune cell infiltration, a considerable number of nasopharyngeal cancer patients still show primary resistance to immune checkpoint blocking therapy. Tumors usually show high expression of PD-L1 and a large amount of immune cell infiltration, but the clinical effect is still poor. This contradiction reflects the inherent drug resistance mechanism that exists before treatment. These mechanisms stem from the virus latent procedure and tumor evolution. Baseline T cell dysfunction is the main cause of primary drug resistance. Long-term exposure to EBV antigen will lead to deep depletion of CD8+ T cells [126,127]. These cells express a variety of inhibitory receptors and lose transcriptional plasticity. The use of PD-1 blocking therapy alone cannot reverse this state. Epigenetic fixation limits the recovery of T cells. The effect function is continuously inhibited. The immune system seems to be activated, but it is actually in a state of inert. Antigen presentation defects further reduce the therapeutic effect. EBV-related tumor cells will down-regulate some components in the MHC I pathway. Viral microRNA inhibits antigen processing genes. The reduction of peptide segment loading will damage the recognition ability of T cells [128]. Even reactivated T cells cannot effectively identify tumor cells. Immune escape persists. This mechanism is an important factor in basic drug resistance. The tumor immune microenvironment also supports intrinsic drug resistance. Medullary dominant inhibition limits the entry and activation of T cells. Tumor-related macrophages and medullary inhibitory cells secrete inhibitory cytokines. These cells themselves also express immune checkpoint lids. The inhibitory effect plays a role at multiple levels. Drug resistance is gradually formed in the early stage. Simple immune checkpoint blocking therapy is not enough to overcome drug resistance. Adaptive immune drug resistance during treatment Some patients initially reacted to immunotherapy, but then relapsed. This model reflects the acquired drug resistance driven by adaptive tumors and immune responses. Therapeutic immune activation reshapes the selection pressure. The tumor also evolved. The plasticity of EBV-driven accelerates this process. Immune checkpoint blocking enhances the conduction of interferon-γ signals in the tumor microenvironment. Interferon signaling enhances antigen presentation and immune recruitment [129,130]. It also induces the immunosuppressive pathway. Tumor cells respond to the immune response by up-regulating PD-L1 and other immune checkpoint ligands. These adaptive changes will weaken the ongoing immune attack, resulting in rapid adaptation resistance. Under immune pressure, tumor cells may also undergo phenotypic evolution. Subclones with reduced immunogenicity gain an advantage. Amplification of antigen deletion variants. The expression pattern of EBV gene has changed. The ability to present viral antigens decreased. Immune recognition is weakened. These changes occur gradually, followed by clinical progress. The adaptive changes of immune cells also play a role. Continuous stimulation during treatment will maintain the immune depletion process. New inhibitory receptors appear. The expression of TIM-3, LAG-3 and TIGIT increased. The metabolic ability of T cells declines. The cytotoxicity is weakened again. The persistence of the immune response is reduced. Drug resistance stabilized. Structural and spatial barriers to durable immune control The mechanism of drug resistance is not limited to molecular signal conduction, but also includes the structural characteristics of the tumor microenvironment. Spatial immune rejection limits the effective immune surveillance in nasopharyngeal cancer. Immune cells gather in the matrix area, and the tumor nest remains closed. Physical isolation reduces cytotoxicity. EB virus promotes this spatial organization through the regulation of chemokines and adhesion molecules. Tumor cells shape the migration patterns of immune cells. Inhibitory medullary cells are located at the tumor boundary and form a functional barrier, which cannot be penetrated by effect T cells. Immune attack is still indirect, and drug resistance changes to structural drug resistance. Fibrosis and matrix remodeling further limit the entry of immune cells. Cancer-related fibroblasts produce extracellular matrix components, which hinder the migration of immune cells. The TGF-β signaling pathway strengthens this barrier. EB virus-driven inflammation promotes matrix activation and increases immune rejection. Treatment pressure can rarely fully destroy these structures. Immune checkpoint blocking enhances immune activation, but does not change the physical entry of immune cells. If the matrix is not remodeled, the immune response will continue to be limited and drug resistance will continue to exist. Persistent control requires strategies to overcome spatial barriers while activating immunity. The primary and acquired drug resistance of nasopharyngeal cancer reflects the complex interaction between EB virus biology, immune adaptation and tumor structure. The virus latent program maintains immune pressure and also enables the virus to escape. The tumor continues to evolve during the treatment process, the function of immune cells is lost over time, and the structural barrier limits the participation of immune cells. Understanding drug resistance as a dynamic, virus-regulated process will help guide future treatment. To overcome drug resistance, it is necessary to adopt a comprehensive strategy, targeting immune checkpoints, viral signaling pathways and tumor microenvironments. Emerging directions and therapeutic opportunities Targeting EBV-driven signaling nodes beyond immune checkpoints In the future, the treatment strategy for nasopharyngeal cancer will increasingly focus on blocking EB virus-driven signaling pathways that maintain immunosuppression. The blocking of immune checkpoints is mainly aimed at the downstream effect, but the virus latent procedure is still intact. Targeting EB virus-related upstream signal nodes such as NF-κB and JAK-STAT pathways may improve the persistence of immune response. These methods are designed to weaken the basis for virus immune escape [131,132]. EB virus latent protein maintains the chronic activation of these pathways. This activation promotes PD-L1 expression, cytokine secretion and medullary cell reprogramming. Pharmacological inhibition of these pathways may reduce immunosuppression and make tumor cells more susceptible to immune attack. Epigenetic regulation is another promising research direction. The latency process of EB virus depends on the epigenetic regulation of the virus and the host gene. Histone modification and DNA methylation affect antigen presentation and immune signal conduction [133,134]. Epigenetic regulators may restore immune visibility. These drugs may also reverse the depletion-related transcription processes in immune cells. The treatment window needs to be carefully evaluated. Direct target virus gene expression is still challenging, but conceptually very attractive. Inhibiting LMP1 signal conduction or destroying the maintenance of viral free bodies may change tumor biology. Due to the strong immunogenicity of LMP1, tumor cells tend to down-regulate its expression [135]. If LMP1 is used as the CAR-T target, it is very easy to screen out LMP1-negative tumor clones, resulting in rapid treatment failure. It has increased concerns on off-target toxicity. Virus biology still needs to be studied in depth in terms of treatment. Progress in this field may change the treatment pattern. EBV-specific immunotherapy and precise immune activation EBV antigenicity provides a unique opportunity for viral-specific immunotherapy for nasopharyngeal cancer. Unlike most solid tumors, nasopharyngeal cancer expresses common viral antigens. These antigens give tumor specificity. The immune targeting has become more accurate. Off-target toxicity is reduced. Transient T cell therapy targeting EBV antigen showed encouraging results in some patients. Amplified EBV-specific cytotoxic T cells identify the viral epitopes presented by tumor cells. These cells mediate direct tumor killing. The persistence and transport of the virus is still a challenge. Due to the existence of spatial physical barriers, even if T cells are activated, they are difficult to cross the interstitium and reach the surface of tumor cells. In addition, the immunosuppressive microenvironment limits the therapeutic effect. The combination of tracing cell therapy with immune checkpoint blocking therapy may enhance the function. The therapeutic EBV vaccine aims to enhance endogenous antiviral immunity. Vaccine strategies target latent antigens, such as EBNA1 and LMP protein [50,136]. These methods aim to amplit the functional T cell group. Vaccine-induced immunity may have a synergistic effect with immunotherapy. Clinical transformation is still in the early stage. Immunosuppression is still an obstacle. The precise immune activation strategy emphasizes selective stimulation rather than systemic immune enhancement. Local immune regulation may reduce systemic toxicity. The methods include intratumor injection of immunostimulants and local expression of cytokines. EBV-positive tumors may have a priority reaction. The presence of viral antigens guides immune targeting. These strategies are in line with the goal of individualized medical treatment. Integrating spatial and single-cell technologies into therapeutic design Emerging technologies provide a new perspective for an in-depth understanding of the complexity of the tumor immune microenvironment of nasopharyngeal cancer. Single cell transcription-omics reveals the heterogeneity of immune cell status, and reveals different depletion procedures and inhibitory phenotypes. These data help us to have a deeper understanding of immune dysfunction, so that the treatment strategy can be more accurate. Spatial analysis technology provides key background information. The positioning of immune cells will affect the therapeutic response, and spatial rejection will limit the immune effectiveness. Identifying spatial immune phenotypes helps to guide treatment choices. Immune-rejected tumors may need matrix regulation, while immune-activated tumors may respond to immune checkpoint blocking therapy. Spatial information helps to improve the accuracy of tumor stratification. Integrating viral gene expression with spatial immune data is a powerful strategy. There are differences in EB virus activity in different regions of the tumor, and viral expression is related to local immunosuppression. Drawing these interaction diagrams can reveal the weak links of treatment, so as to target the main inhibitory microenvironment and improve the accuracy of treatment. Computational modeling and artificial intelligence have further enhanced this integration. Multi-group data analysis can identify patterns those traditional methods cannot find. Predictive models can predict treatment response and drug resistance. These tools support the design of a reasonable combination treatment scheme. Future clinical trials may prospectively incorporate this stratification method. Precise immunotherapy will be possible. The emerging direction of nasopharyngeal cancer immunotherapy emphasizes the integration of viral biology, immunomodulation and spatial environment. EB virus is still the core organizational principle. The success of treatment depends on the simultaneous solution of immune activation and virus-driven immunosuppression. Although LMP1 is a membrane protein that is difficult to develop into a drug, targeting its downstream key nodes such as specific TRAF binding domains or STAT3 may be crucial. The LMP1 can be degraded by PROTAC technology. Therefore, the combination of immune checkpoint blocking with EB virus targeting and microenvironment regulation strategy is promising. Continuous innovation will make nasopharyngeal cancer a model of virus-related cancer immunotherapy. The future progress of nasopharyngeal cancer treatment depends on the integration of viral biology, immunospectroscopy and spatial background into clinical decision-making. Conclusions The evidence reviewed in this article supports a unified concept: EBV is not a passive carcinogenic passenger, but an active builder of immune escape in nasopharyngeal cancer. EBV latent proteins and non-coding RNA reprogram the host signaling pathway to regulate inflammation and immunity [24,42]. LMP1-driven NF-κB and JAK-STAT signaling pathways maintain chronic inflammatory activation while promoting immune tolerance. Viral microRNA inhibits antigen presentation and immune surveillance. These mechanisms play a role in tumor cells and extend to the immune and matrix chambers. The tumor immune microenvironment presents a virus-shaped ecosystem. This framework solves the long-standing paradox of nasopharyngeal cancer: it is a tumor rich in immune cells but immunosuppressive. Continuous viral antigen stimulation will recruit immune cells. The EBV-driven suppression network will limit its function. Under continuous immune pressure, adaptive drug resistance will continue to evolve. Spatial rejection further limits the participation of cytotoxic drugs. Taking EBV as the core organizer has changed the conceptual basis of nasopharyngeal cancer research. The traditional diagnosis of “PD-L1 positive” may be outdated. What we need is “spatial typing.” This view redefines the failure of treatment as the success of viral immunoengineering, rather than immunodeficiency. This redefinition is conducive to the design of a reasonable treatment plan. Virus-related cancers have a common immune challenge. EBV-driven immune escape clarifies how chronic antigen exposure and immune regulation interact. The experience gained from nasopharyngeal cancer may provide reference for the treatment of other virus-driven malignant tumors. The field is at a turning point. Combining immunotherapy with viral biology will determine the success of the next generation of treatment. Acknowledgements L H, X X, and Q L: the main article conception, data collection and processing. K Y and Y T: Methodology, Writing. T S and Q L: Reviewing and Editing. Funding Statement This work was supported by the General Program of Liaoning Provincial Natural Science Foundation [2025-MS-227]; the Liaoning Province Science and Technology Plan Joint Program [2024-MSLH-575]; and the Liaoning Provincial Science and Technology Plan Joint Program [2023JH2/101700139]. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement There is no data associated with this research. References Associated Data Data Availability Statement There is no data associated with this research.